ProBion Innovation Sweden (PISA) has announced the results of a study using its own ProBion Matrix Technology on colon cancer patients altering colon-cancer-associated microbiota to non-cancer microbiota.
Research at Sahlgrenska University Hospital in Gothenburg showed that colon-cancer-associated microbial signature was modified due to probiotic intervention, characterised by the enrichment of butyrate-producing bacteria in the intestinal tissue along with a regenerated intestinal microbiome profile closely resembling healthy individuals.
"Colon cancer patients harbour a distinct microbiota signature in the tumour tissue and nearby mucosa," says principal investigator Dr Yvonne Wettergren. "The ProBion Clinica regimen resulted in an overabundance of the beneficial faecalibacterium and clostridiales spp bacteria in the tumour tissue, non-tumour mucosa, as well as in the faecal microbiota."
"There is a great unmet need for new CRC innovative research and treatment options, " adds Dr Victoria Rotter Sopasakis, co-founder and CEO of PISA. "PISA is very excited about the results and is taking this concept a step further. I am pleased to announce the planning of a new trial study on the effects of ProBion Clinica on patients with premalignant adenomas".
"Many diseases are directly associated with a dysfunctional gut microbiota. Probiotics have a huge potential to improve these conditions and/or improve the efficacy of traditional treatments already in use," says Dr Lennart Cedgård, co-founder of PISA and inventor of the ProBion Matrix Technology.
"However, in order to test and evaluate this, it is imperative to create a formulation that delivers viable, functional and safe probiotic bacteria to the correct location. The ProBion Matrix elegantly meets all these criteria and current results could be the tipping point for a paradigm shift."
Shielding the interior bacteria from moisture and aggressive acids enables prolonged viability of the bacteria with 80-85% live and non-compromised cells for 30 months at room temperature.